Updated Jul 16, 2026
MAETZOLD DEREK J has filed 6 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $7.63M.

Derek J. Maetzold is an accomplished executive in the biotechnology sector, currently serving as the President and Chief Executive Officer of Castle Biosciences Inc. He has played a significant role in the company's growth and development, focusing on innovative diagnostic solutions for skin cancer and other diseases.
| Role | Pres. & Chief Exec. Officer, Director |
|---|---|
| Notability | 75/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $24.29 | $7K |
| 2026-07-06 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $24.29 | $7K |
| 2026-07-06 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $24.29 | $7K |
| 2026-07-06 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $24.29 | $7K |
| 2026-07-06 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 1.2K | $24.29 | $28K |
| 2026-07-06 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 1.4K | $24.29 | $33K |
| 2026-07-06 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 6.2K | $24.29 | $151K |
| 2026-07-06 | CSTL | CASTLE BIOSCIENCES INC | M — Option exercise | 6.2K | $2.39 | $15K |
| 2026-06-17 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $20.66 | $6K |
| 2026-06-17 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $20.66 | $6K |
| 2026-06-17 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $20.66 | $6K |
| 2026-06-17 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $20.66 | $6K |
| 2026-06-17 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 1.2K | $20.66 | $24K |
| 2026-06-17 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 1.4K | $20.66 | $28K |
| 2026-06-17 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 550 | $20.66 | $11K |
| 2026-06-17 | CSTL | CASTLE BIOSCIENCES INC | M — Option exercise | 550 | $2.39 | $1K |
| 2026-06-03 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $20.86 | $6K |
| 2026-06-03 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $20.86 | $6K |
| 2026-06-03 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $20.86 | $6K |
| 2026-06-03 | CSTL | CASTLE BIOSCIENCES INC | S — Open-market sale | 278 | $20.86 | $6K |
Derek J. Maetzold is an accomplished executive in the biotechnology sector, currently serving as the President and Chief Executive Officer of Castle Biosciences Inc. He has played a significant role in the company's growth and development, focusing on innovative diagnostic solutions for skin cancer and other diseases.…
6 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 187 open-market sales ($7.63M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live MAETZOLD DEREK J profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.